NO20025964L - Ny interferon for behandling av multippel sklerose - Google Patents

Ny interferon for behandling av multippel sklerose

Info

Publication number
NO20025964L
NO20025964L NO20025964A NO20025964A NO20025964L NO 20025964 L NO20025964 L NO 20025964L NO 20025964 A NO20025964 A NO 20025964A NO 20025964 A NO20025964 A NO 20025964A NO 20025964 L NO20025964 L NO 20025964L
Authority
NO
Norway
Prior art keywords
treatment
multiple sclerosis
new interferon
interferon
new
Prior art date
Application number
NO20025964A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025964D0 (no
Inventor
Edward M Croze
Daryl Faulds
T Charis Wagner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20025964D0 publication Critical patent/NO20025964D0/no
Publication of NO20025964L publication Critical patent/NO20025964L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20025964A 2000-06-16 2002-12-12 Ny interferon for behandling av multippel sklerose NO20025964L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis
PCT/US2001/041022 WO2001095929A2 (en) 2000-06-16 2001-06-18 Interferon for treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
NO20025964D0 NO20025964D0 (no) 2002-12-12
NO20025964L true NO20025964L (no) 2003-02-14

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025964A NO20025964L (no) 2000-06-16 2002-12-12 Ny interferon for behandling av multippel sklerose

Country Status (22)

Country Link
US (1) US20020025304A1 (et)
EP (1) EP1289541A2 (et)
JP (1) JP2004505021A (et)
KR (1) KR20030009529A (et)
CN (1) CN1436086A (et)
AU (1) AU2001267099A1 (et)
BG (1) BG107370A (et)
BR (1) BR0111852A (et)
CA (1) CA2413077A1 (et)
CZ (1) CZ20024094A3 (et)
EE (1) EE200200693A (et)
HU (1) HUP0300787A2 (et)
IL (1) IL152996A0 (et)
LT (1) LT2002123A (et)
MX (1) MXPA02012308A (et)
NO (1) NO20025964L (et)
NZ (1) NZ522849A (et)
PL (1) PL359562A1 (et)
RU (1) RU2003100517A (et)
SI (1) SI21080A (et)
SK (1) SK17612002A3 (et)
WO (1) WO2001095929A2 (et)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2004046365A2 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1712992A1 (en) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Updating of data instructions
EP2536435B1 (en) * 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
WO2017134306A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Cd8 binding agents
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
PL317197A1 (en) * 1994-05-10 1997-03-17 Immulogic Pharma Corp Compositions for and method of treating sclerosis multiplex
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
CN1299285A (zh) * 1998-05-29 2001-06-13 拜奥根有限公司 重组人干扰素β－1A(IFN－β－1A)制剂
WO2000017361A2 (en) * 1998-09-18 2000-03-30 Zymogenetics, Inc. Interferon-epsilon
WO2001079289A2 (en) * 2000-04-14 2001-10-25 Zymogenetics, Inc. Human interferon, zinf2

Also Published As

Publication number Publication date
BG107370A (en) 2003-11-28
EE200200693A (et) 2004-06-15
NZ522849A (en) 2004-05-28
MXPA02012308A (es) 2003-04-25
EP1289541A2 (en) 2003-03-12
JP2004505021A (ja) 2004-02-19
SK17612002A3 (sk) 2003-08-05
KR20030009529A (ko) 2003-01-29
US20020025304A1 (en) 2002-02-28
RU2003100517A (ru) 2004-06-27
WO2001095929A2 (en) 2001-12-20
NO20025964D0 (no) 2002-12-12
CZ20024094A3 (cs) 2003-05-14
IL152996A0 (en) 2003-06-24
HUP0300787A2 (hu) 2003-07-28
BR0111852A (pt) 2003-05-20
CN1436086A (zh) 2003-08-13
CA2413077A1 (en) 2001-12-20
AU2001267099A1 (en) 2001-12-24
LT2002123A (en) 2003-06-25
SI21080A (sl) 2003-06-30
PL359562A1 (en) 2004-08-23
WO2001095929A3 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
EE05020B1 (et) Glburiidi ravimkoostis
NO20040253L (no) Fremgangsmater for behandling av leverfibroser
DE60126814D1 (de) Inhalation von stickoxid
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20041968L (no) Anvendelse av cystationin
NO20031525D0 (no) Kjemokinmutanter i behandlingen av multippel sklerose
NO20013337L (no) Ny behandling
NO20025964D0 (no) Ny interferon for behandling av multippel sklerose
FR2791258B1 (fr) Composition amincissante
NO20032769L (no) Kombinasjonsmetode for behandling av virale infeksjoner
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
DE60007360D1 (de) Amorphe modifikation von torasemid
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
GB0114231D0 (en) Treatment of multiple sclerosis
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
DE60207900D1 (de) "Suspend"-Paketübertrager
ITMI20011820A0 (it) Trattamento di ustioni
AU2002366793A1 (en) Improved lilly of the valley aromachemicals
NO20025765D0 (no) Kombinasjonssett for behandling av malaria
NO20023702L (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20005856D0 (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application